Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Sold by Marathon Trading Investment Management LLC

Marathon Trading Investment Management LLC lessened its position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 79.8% in the 2nd quarter, Holdings Channel reports. The fund owned 19,116 shares of the company’s stock after selling 75,284 shares during the period. Marathon Trading Investment Management LLC’s holdings in Black Diamond Therapeutics were worth $89,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in BDTX. Susquehanna Fundamental Investments LLC purchased a new position in shares of Black Diamond Therapeutics in the 1st quarter valued at about $82,000. SG Americas Securities LLC purchased a new position in shares of Black Diamond Therapeutics in the 2nd quarter valued at about $108,000. Jump Financial LLC increased its holdings in shares of Black Diamond Therapeutics by 245.0% in the 4th quarter. Jump Financial LLC now owns 38,888 shares of the company’s stock valued at $109,000 after purchasing an additional 27,616 shares in the last quarter. Pale Fire Capital SE purchased a new position in shares of Black Diamond Therapeutics in the 4th quarter valued at about $144,000. Finally, Rhumbline Advisers increased its holdings in shares of Black Diamond Therapeutics by 10,334.3% in the 2nd quarter. Rhumbline Advisers now owns 46,850 shares of the company’s stock valued at $218,000 after purchasing an additional 46,401 shares in the last quarter. Institutional investors and hedge funds own 95.47% of the company’s stock.

Wall Street Analysts Forecast Growth

BDTX has been the subject of several recent research reports. Wedbush restated an “outperform” rating and set a $16.00 target price on shares of Black Diamond Therapeutics in a report on Tuesday, September 10th. Raymond James initiated coverage on shares of Black Diamond Therapeutics in a report on Wednesday, July 31st. They set an “outperform” rating and a $20.00 target price for the company. Piper Sandler restated an “overweight” rating and set a $12.00 target price on shares of Black Diamond Therapeutics in a report on Wednesday, July 3rd. Finally, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Black Diamond Therapeutics in a report on Wednesday.

Black Diamond Therapeutics Price Performance

Black Diamond Therapeutics stock opened at $4.73 on Thursday. Black Diamond Therapeutics, Inc. has a 12-month low of $1.62 and a 12-month high of $7.66. The stock has a market capitalization of $266.08 million, a P/E ratio of -2.85 and a beta of 2.49. The firm’s 50-day moving average is $5.72 and its two-hundred day moving average is $5.35.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.03. As a group, analysts forecast that Black Diamond Therapeutics, Inc. will post -1.4 EPS for the current year.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.